quinoxalines has been researched along with tetrazanbigen in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Gan, L; Gan, Z; He, B; Hu, X; Li, Y; Liu, R; Wan, C; Wang, J; Yu, Y | 1 |
1 other study(ies) available for quinoxalines and tetrazanbigen
| Article | Year |
|---|---|
TNBG-5602, a novel derivative of quinoxaline, inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor γ in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Gonanes; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; PPAR gamma; Proliferating Cell Nuclear Antigen; Quinoxalines; Up-Regulation | 2019 |